Oncimmune (LON:ONC) Posts Earnings Results

Oncimmune (LON:ONC) released its quarterly earnings results on Monday. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oncimmune had a negative return on equity of 760.96% and a net margin of 586.08%.

Oncimmune Stock Performance

Shares of Oncimmune stock opened at GBX 9.45 ($0.12) on Monday. Oncimmune has a 12 month low of GBX 8 ($0.10) and a 12 month high of GBX 31 ($0.38). The company has a debt-to-equity ratio of 806.85, a current ratio of 1.13 and a quick ratio of 0.63. The stock has a market capitalization of £7.01 million, a price-to-earnings ratio of -315.00 and a beta of 1.19. The firm’s fifty day simple moving average is GBX 13.48 and its 200-day simple moving average is GBX 14.81.

About Oncimmune

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.